SEC Form 4 · accession 0001171843-17-007216
IMMUNOMEDICS INC · IMMU
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian A Markison
Director
Period of report
Nov 20, 2017
Accepted (ET)
Nov 21, 2017 · 5:00 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000722830
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Nov 20, 2017 | M | 15,000 | $3.16 | A | 99,178 | D | |
| Common StockF1,F2 | Nov 20, 2017 | S | 8,390 | $11.886 | D | 90,788 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (right to buy) | $3.16 | Nov 20, 2017 | M | 15,000 | D | Dec 1, 2010 | Dec 1, 2017 | Common Stock, par value $0.01 per share | 15,000 | 0 | D |
Explanation of responses
- F1The price in column 4 is a weighted average price. The prices actually received by the reporting person in this transaction range from $11.88 to $11.92.
- F2The reporting person has provided to the issuer, and the issuer will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range reported.